The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of PET/CT response assessment prior to CAR T-cell infusion with outcomes after CAR T-cell therapy in aggressive B-cell lymphomas.
 
Alexandra Nader
No Relationships to Disclose
 
Hwan Lee
No Relationships to Disclose
 
Mark Sellmyer
Stock and Other Ownership Interests - Vellum Biosciences
Honoraria - AstraZeneca/MedImmune; AstraZeneca/MedImmune
Research Funding - Bristol-Myers Squibb/Celgene
Patents, Royalties, Other Intellectual Property - Destabilizing Domain Technology (held by Stanford) licensed to Obsidian Tx
 
Daniel Jeffrey Landsburg
Consulting or Advisory Role - Celgene; Karyopharm Therapeutics; MorphoSys
Speakers' Bureau - Seagen
Research Funding - Curis (Inst); Takeda (Inst); Triphase Accelerator Corp (Inst)
 
Sunita Nasta
Consulting or Advisory Role - Merck; MorphoSys
Research Funding - Aileron Therapeutics; Atara Biotherapeutics; Debiopharm Group; Forty Seven; Incyte; Millennium; Pharmacyclics/Janssen; Rafael Pharmaceuticals; Roche/Genentech
 
James Gerson
Consulting or Advisory Role - Abbvie; Pharmacyclics; Seagen
Research Funding - Loxo
 
Jakub Svoboda
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; Atara Biotherapeutics; BMS; Genmab; Imbrium Therapeutics; Pharmacyclics; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Imbrium Therapeutics
 
Stefan K. Barta
Honoraria - Mundipharma; Seagen
Consulting or Advisory Role - Atara Biotherapeutics; Janssen Oncology; Seagen
Research Funding - Bayer (Inst); Celgene; Merck (Inst); Seagen (Inst); Takeda
Travel, Accommodations, Expenses - Curis
 
Elizabeth Weber
Honoraria - Janssen; Novartis
Consulting or Advisory Role - Novartis
 
Stephen J. Schuster
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Alimera Sciences; BeiGene; Celgene; Genentech/Roche; Juno Therapeutics; Loxo; Nordic Nanovector; Novartis; Tessa Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)
 
Elise A. Chong
Consulting or Advisory Role - Bristol-Myers Squibb; Kite, a Gilead company; Novartis; Tessa Therapeutics